Fencing off the increased competition from biosimilars and generics, combination products and value-added features are now seen as a differentiated route to pharma/ drug developers as a lifecycle maximization strategy.
Over the last 2 years, more emphasis is placed on understanding market trends and establishing a robust framework of lifecycle management (LCM) amongst industry leaders, especially from a design control and risk mitigation perspective.
At the same time, the surge of digital platforms and connected technology presents lucrative opportunities to combo products developers – not only from a commercial perspective but also patient adherence, which will subsequently aids competitive advantage.
So what’s the best approach to managing your LCM? How to tailor your program and ensure it’s fit-for-purpose and cost-efficient?
This 3-day summit will focus on LCM of combination devices, equipping the community with a holistic view of the following areas through operational case studies:
- LCM strategies tailored for combination products
- Quality risk management for ageing combo products
- Design control and testing techniques during combination product upgrade
Join us in Boston to be part of the community!